Literature DB >> 26192354

Adjuvant potential of resiquimod with inactivated Newcastle disease vaccine and its mechanism of action in chicken.

Swati Sachan1, Saravanan Ramakrishnan2, Arunsaravanakumar Annamalai1, Bal Krishan Sharma1, Hina Malik3, B C Saravanan4, Lata Jain5, Meeta Saxena6, Ajay Kumar6, Narayanan Krishnaswamy7.   

Abstract

Resiquimod (R-848), an imidazoquinoline compound, is a potent synthetic Toll-like receptor (TLR) 7 agonist. Although the solitary adjuvant potential of R-848 is well established in mammals, such reports are not available in avian species hitherto. Hence, the adjuvant potential of R-848 was tested in SPF chicken in this study. Two week old chicks were divided into four groups (10 birds/group) viz., control (A), inactivated Newcastle disease virus (NDV) vaccine prepared from velogenic strain (B), commercial oil adjuvanted inactivated NDV vaccine prepared from lentogenic strain (C) and inactivated NDV vaccine prepared from velogenic strain with R-848 (D). Booster was given two weeks post primary vaccination. Humoral immune response was assessed by haemagglutination inhibition (HI) test and ELISA while the cellular immune response was quantified by lymphocyte transformation test (LTT) and flow cytometry post-vaccination. Entire experiment was repeated twice to check the reproducibility. Highest HI titre was observed in group D at post booster weeks 1 and 2 that corresponds to mean log2 HI titre of 6.4 ± 0.16 and 6.8 ± 0.13, respectively. The response was significantly higher than that of group B or C (P<0.01). LTT stimulation index (P ≤ 0.01) as well as CD4(+) and CD8(+) cells in flow cytometry (P<0.05) were significantly high and maximum in group D. Group D conferred complete protection against virulent NDV challenge, while it was only 80% in group B and C. To understand the effects of R-848, the kinetics of immune response genes in spleen were analyzed using quantitative real-time PCR after R-848 administration (50 μg/bird, i.m. route). Resiquimod significantly up-regulated the expression of IFN-α, IFN-β, IFN-γ, IL-1β, IL-4, iNOS and MHC-II genes (P<0.01). In conclusion, the study demonstrated the adjuvant potential of R-848 when co-administered with inactivated NDV vaccine in SPF chicken which is likely due to the up-regulation of immune response genes.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adjuvant; Chicken; Cytokines; Immune response genes; Newcastle disease; Resiquimod; TLR agonist

Mesh:

Substances:

Year:  2015        PMID: 26192354     DOI: 10.1016/j.vaccine.2015.07.016

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  12 in total

1.  Co-administration of toll-like receptor (TLR)-3 and 4 ligands augments immune response to Newcastle disease virus (NDV) vaccine in chicken.

Authors:  T R Kannaki; E Priyanka; M R Reddy
Journal:  Vet Res Commun       Date:  2019-08-24       Impact factor: 2.459

2.  Evaluation of different combination of pam2CSK4, poly (I:C) and imiquimod enhance immune responses to H9N2 avian influenza antigen in dendritic cells and duck.

Authors:  Aiguo Zhang; Deyin Li; Chao Song; Huiyuan Jing; Hongfei Li; Junxian Mi; Guizhi Zhang; Shuangxing Jin; Xiaoli Ren; Heping Huangfu; Dongmei Shi; Ruiai Chen
Journal:  PLoS One       Date:  2022-07-19       Impact factor: 3.752

3.  Evaluation of the Protective Efficacy of Poly I:C as an Adjuvant for H9N2 Subtype Avian Influenza Inactivated Vaccine and Its Mechanism of Action in Ducks.

Authors:  Aiguo Zhang; Hanzhang Lai; Jiahua Xu; Wenke Huang; Yufu Liu; Dawei Zhao; Ruiai Chen
Journal:  PLoS One       Date:  2017-01-30       Impact factor: 3.240

4.  Transcriptome Analysis in Spleen Reveals Differential Regulation of Response to Newcastle Disease Virus in Two Chicken Lines.

Authors:  Jibin Zhang; Michael G Kaiser; Melissa S Deist; Rodrigo A Gallardo; David A Bunn; Terra R Kelly; Jack C M Dekkers; Huaijun Zhou; Susan J Lamont
Journal:  Sci Rep       Date:  2018-01-19       Impact factor: 4.379

5.  Validation of immunomodulatory effects of lipopolysaccharide through expression profiling of Th1 and Th2 biased genes in Newcastle disease virus vaccinated indigenous chicken.

Authors:  Rabia Bhardwaj; Ramneek Verma; Dipak Deka; P P Dubey; J S Arora; R S Sethi; T C Tolenkhomba; C S Mukhopadhyay
Journal:  Vet World       Date:  2018-04-09

6.  In Ovo Delivered Toll-Like Receptor 7 Ligand, Resiquimod Enhances Host Responses against Infectious Bronchitis Corona Virus (IBV) Infection.

Authors:  Upasama De Silva Senapathi; Mohamed Aboelkhair; Kekungu Puro; Mariam Ali; Aruna Amarasinghe; M Sarjoon Abdul-Cader; Guido Van Marle; Markus Czub; Mohamed Faizal Abdul-Careem
Journal:  Vaccines (Basel)       Date:  2020-04-15

7.  Combination of TLR2 and TLR3 agonists derepress infectious bursal disease virus vaccine-induced immunosuppression in the chicken.

Authors:  Khalid Bashir; Deepthi Kappala; Yogendra Singh; Javeed Ahmad Dar; Asok Kumar Mariappan; Ajay Kumar; Narayanan Krishnaswamy; Sohini Dey; Madhan Mohan Chellappa; Tapas Kumar Goswami; Vivek Kumar Gupta; Saravanan Ramakrishnan
Journal:  Sci Rep       Date:  2019-06-03       Impact factor: 4.379

8.  Immunomodulatory Potential of Tinospora cordifolia and CpG ODN (TLR21 Agonist) against the Very Virulent, Infectious Bursal Disease Virus in SPF Chicks.

Authors:  Swati Sachan; Kuldeep Dhama; Shyma K Latheef; Hari Abdul Samad; Asok Kumar Mariappan; Palanivelu Munuswamy; Rajendra Singh; Karam Pal Singh; Yashpal Singh Malik; Raj Kumar Singh
Journal:  Vaccines (Basel)       Date:  2019-09-04

Review 9.  Newcastle disease vaccines-A solved problem or a continuous challenge?

Authors:  Kiril M Dimitrov; Claudio L Afonso; Qingzhong Yu; Patti J Miller
Journal:  Vet Microbiol       Date:  2016-12-16       Impact factor: 3.293

10.  Resiquimod enhances mucosal and systemic immunity against avian infectious bronchitis virus vaccine in the chicken.

Authors:  Javaid Jeelani Matoo; Khalid Bashir; Ajay Kumar; Narayanan Krishnaswamy; Sohini Dey; Madhan Mohan Chellappa; Saravanan Ramakrishnan
Journal:  Microb Pathog       Date:  2018-04-07       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.